2
Supplementary Figure 2 HEK293 MRC-5 SKOV-3 MDAH-2774 anti-IGFBP-5 anti--actin Igfbp5 mRNA Gapdh mRNA 0 500 1000 1500 2000 tumor volume (mm 2 ) mock IGFBP-5 * IGFBP-5 mock number of blood vessels per tumor section 0 5 10 15 20 anti-CD31 (PECAM-1) IGFBP-5 mock mock IGFBP-5 * A B Supplementary Figure 1

Supplementary Figure 2

  • Upload
    ely

  • View
    34

  • Download
    0

Embed Size (px)

DESCRIPTION

A. HEK293. MRC-5. SKOV-3. MDAH-2774. Igfbp5 mRNA. Gapdh mRNA. anti-IGFBP-5. anti- b -actin. B. mock. IGFBP-5. mock. IGFBP-5. 2000. 1500. anti-CD31 (PECAM-1). tumor volume (mm 2 ). 1000. *. 500. 0. mock. IGFBP-5. 20. 15. number of blood vessels per tumor section. 10. - PowerPoint PPT Presentation

Citation preview

Page 1: Supplementary Figure 2

Supplementary Figure 2

HEK293 MRC-5 SKOV-3 MDAH-2774

anti-IGFBP-5

anti--actin

Igfbp5 mRNA

Gapdh mRNA

0

500

1000

1500

2000

tum

or v

olum

e (m

m2)

mock IGFBP-5

*

IGFBP-5mock

num

ber

of b

lood

ves

sels

per

tum

or s

ectio

n

0

5

10

15

20

anti-CD31 (PECAM-1)

IGFBP-5mock

mock IGFBP-5

*

A

B

Supplementary Figure 1

Page 2: Supplementary Figure 2

Supplementary Figure 3

anti-IGFBP-5

anti--actin

untreated 10 ng/ml 50 ng/ml 100 ng/ml

VEGF

anti-IGFBP-5

anti--actin

Igfbp5 mRNA

Gapdh mRNA

untreated IGF-1 (100 ng/ml)

Supplementary Figure 4


Supplementary Figure 1 - Welcome to the UCLA …€¦ ·  · 2016-06-151 Supplementary Figure 1 Supplementary Figure 1. ... Supplementary Figure 5 Supplementary Figure 5. ... JP10089

Supplementary Figure 1 - Welcome to the UCLA …€¦ ·  · 2016-06-151 Supplementary Figure 1 Supplementary Figure 1. ... Supplementary Figure 5 Supplementary Figure 5. ... JP10089

Documents
Supplementary Material Figure 2. Phylogenetic

Supplementary Material Figure 2. Phylogenetic

Documents
Supplementary Figure 1. Supplementary Figure 2 Supplementary Figure 3 A B

Supplementary Figure 1. Supplementary Figure 2 Supplementary Figure 3 A B

Documents
Supplementary Figure 2

Supplementary Figure 2

Documents
Supplementary figure 1

Supplementary figure 1

Documents
Supplementary information for: Discovery and … · Supplementary Figure S2 Supplementary Figure S3 Supplementary Figure S4 Supplementary Figure S5 Supplementary Figure S6 Supplementary

Supplementary information for: Discovery and … · Supplementary Figure S2 Supplementary Figure S3 Supplementary Figure S4 Supplementary Figure S5 Supplementary Figure S6 Supplementary

Documents
Supplementary appendix · Supplementary Figure 1. Funnel Plot for total symptoms Supplementary Figure 2. ... positive, negative and general symptom scores are not reported we estimated

Supplementary appendix · Supplementary Figure 1. Funnel Plot for total symptoms Supplementary Figure 2. ... positive, negative and general symptom scores are not reported we estimated

Documents
Supplementary Figure 1. Secondary Assays (A) Schematic ...genepath.med.harvard.edu/perrimon/papers/KnybakkenSupp.pdf · Supplementary Figure 2. Phosphorylation of Fu and Cos2 are

Supplementary Figure 1. Secondary Assays (A) Schematic ...genepath.med.harvard.edu/perrimon/papers/KnybakkenSupp.pdf · Supplementary Figure 2. Phosphorylation of Fu and Cos2 are

Documents
media.nature.com · 1 Supplementary Materials Supplementary Table S1 Supplementary Table S2 Supplementary Table S3 Supplementary Figure S1 Supplementary Figure S2 Supplementary Figure

media.nature.com · 1 Supplementary Materials Supplementary Table S1 Supplementary Table S2 Supplementary Table S3 Supplementary Figure S1 Supplementary Figure S2 Supplementary Figure

Documents
SUPPLEMENTARY MATERIAL: SUPPLEMENTARY FIGURE 2cambridge.org:id:article:S... · SUPPLEMENTARY MATERIAL: SUPPLEMENTARY FIGURE 2 Image gallery to accompany John Robb (2015), “Prehistoric

SUPPLEMENTARY MATERIAL: SUPPLEMENTARY FIGURE 2cambridge.org:id:article:S... · SUPPLEMENTARY MATERIAL: SUPPLEMENTARY FIGURE 2 Image gallery to accompany John Robb (2015), “Prehistoric

Documents
Supplementary Figure 1 - dm5migu4zj3pb.cloudfront.net · Supplementary Figure 1 A B 0 10 20 30 40 ... Oral glucose tolerance test (OGTT) ... Supplementary Figure 2 A) ) 0.5 0 1 1.5

Supplementary Figure 1 - dm5migu4zj3pb.cloudfront.net · Supplementary Figure 1 A B 0 10 20 30 40 ... Oral glucose tolerance test (OGTT) ... Supplementary Figure 2 A) ) 0.5 0 1 1.5

Documents
Supplementary Figure S26

Supplementary Figure S26

Documents
Supplementary Figure 1

Supplementary Figure 1

Documents
Supplementary Figure S1

Supplementary Figure S1

Documents
Supplementary figure 5

Supplementary figure 5

Documents
Supplementary Figure 1 - Nature · Supplementary Figure 1 ... Supplementary Figure 3. Activation of HIF-1 activity by UCHL1 overexpression. ... EMT6/EF-Luc/EV-1, 2 and

Supplementary Figure 1 - Nature · Supplementary Figure 1 ... Supplementary Figure 3. Activation of HIF-1 activity by UCHL1 overexpression. ... EMT6/EF-Luc/EV-1, 2 and

Documents
Supplementary figure 1A

Supplementary figure 1A

Documents
Supplementary Figure · 2015. 1. 14. · 2 Supplementary Figure Supplementary Figure 1. Standard and Selected Samples. Chen et al. (2015) Asian Australas. J. Anim. Sci. 28:158-165

Supplementary Figure · 2015. 1. 14. · 2 Supplementary Figure Supplementary Figure 1. Standard and Selected Samples. Chen et al. (2015) Asian Australas. J. Anim. Sci. 28:158-165

Documents
SUPPLEMENTARY FIGURE 2 - AACR Journals · 2015. 11. 26. · Vehicle ML264 (2 x 25 mg/kg) KL F5 # 1 A KL F5 # 2 KL F5 # 3 Supplementary Figure 2. Title: SUPPLEMENTARY FIGURE 2 Created

SUPPLEMENTARY FIGURE 2 - AACR Journals · 2015. 11. 26. · Vehicle ML264 (2 x 25 mg/kg) KL F5 # 1 A KL F5 # 2 KL F5 # 3 Supplementary Figure 2. Title: SUPPLEMENTARY FIGURE 2 Created

Documents
SUPPLEMENTARY INFORMATIONmendel.stanford.edu/SidowLab/pdfs/2011ValouevEtAl_Supp.pdf · Supplementary Figure 2 Supplementary Figure 2. Schematic representation of in vitro reconstitution

SUPPLEMENTARY INFORMATIONmendel.stanford.edu/SidowLab/pdfs/2011ValouevEtAl_Supp.pdf · Supplementary Figure 2 Supplementary Figure 2. Schematic representation of in vitro reconstitution

Documents
Supplementary Figure 2

Supplementary Figure 2

Documents
Supplementary Materials Supplementary Figure Legends

Supplementary Materials Supplementary Figure Legends

Documents
Supplementary Figure 1A HNF4AWNT5AVANGL1PCLB1 Supplementary Figure 1B Supplementary Figure 1. (A) HNF4A TFBSs of the three genes: VANGL1, WNT5A and PLCB1

Supplementary Figure 1A HNF4AWNT5AVANGL1PCLB1 Supplementary Figure 1B Supplementary Figure 1. (A) HNF4A TFBSs of the three genes: VANGL1, WNT5A and PLCB1

Documents
Supplementary Figure 1 a b - Nature · Supplementary Figure 1. ... Supplementary Figure 2 ... Il-1b Il-6 Ifnγ Tnfa Mcp1 F4/80 Crp Saa Sap iWAT WT-Ctrl WT-Tuni KO-Ctrl

Supplementary Figure 1 a b - Nature · Supplementary Figure 1. ... Supplementary Figure 2 ... Il-1b Il-6 Ifnγ Tnfa Mcp1 F4/80 Crp Saa Sap iWAT WT-Ctrl WT-Tuni KO-Ctrl

Documents
images.nature.com · Web viewSupplementary Figure 7 Supplementary Figure 3 Supplementary Figure 1 Supplementary Materials Supplementary Figures S1-S7 Supplementary Tables S1-S7 Clinical

images.nature.com · Web viewSupplementary Figure 7 Supplementary Figure 3 Supplementary Figure 1 Supplementary Materials Supplementary Figures S1-S7 Supplementary Tables S1-S7 Clinical

Documents
Supplementary figure 1

Supplementary figure 1

Documents
Supplementary Figure 2A

Supplementary Figure 2A

Documents
Supplementary figure 2. Guillemin et al. Supplementary figure 2. Expression of BCL2L10 in human oocytes analyzed by immunofluorescence. Detection of BCL2L10

Supplementary figure 2. Guillemin et al. Supplementary figure 2. Expression of BCL2L10 in human oocytes analyzed by immunofluorescence. Detection of BCL2L10

Documents
images.nature.com · Web viewVahid Asnafi2, Elizabeth Macintyre 2, Els Verhoeyen1,3 and Melania Tesio2 SUPPLEMENTA L DATA Supplementary figure 1 Supplementary figure 2 Supplementary

images.nature.com · Web viewVahid Asnafi2, Elizabeth Macintyre 2, Els Verhoeyen1,3 and Melania Tesio2 SUPPLEMENTA L DATA Supplementary figure 1 Supplementary figure 2 Supplementary

Documents
Supplementary figure 2

Supplementary figure 2

Documents